Clinical trials: Anthracyclines
TNBC, Triple Negative Breast Cancer
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
Triple-negative breast cancer (TNBC) accounts for about 20% of breast cancers, is poorly differentiated, progresses rapidly, and frequently recurs, making it the subtype with the worst prognosis.
- Trial name
- NCT07178171
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pirarubicin, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xijing Hospital
Childhood Cancers
Cardiovascular Function in Adult Survivors of Childhood Malignancies
Anthracyclines have been used commonly to treat children with solid tumours and haematological malignancies and have led to their increased survival. Nonetheless, anthracycline has the side effect of cardiotoxicity.
- Trial name
- NCT01415999
- Where
- China
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Lymphoma
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00987493
- Testing
- rituximab, bendamustine hydrochloride, lenalidomide
- Where
- 16 sites in Switzerland
- Volunteers
- 49 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer
Natriuretic Peptide Concentrations of B-type (BNP) During Anesthesia in Patients Previously Sensitized to Anthracyclines
The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical and echocardiographic monitoring. In the case of treatment for breast cancer, surgery requiring general anesthesia may follow…
- Trial name
- PEP-NAT-B (NCT01754597)
- Testing
- Dosage of B-type natriuretic peptide (NT-proBNP)
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Institut Bergonié
Breast Cancer, HER-2 Positive Breast Cancer
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
The purpose of this study is to evaluate the efficacy in terms of the pathological complete response (pCR) rate and the efficacy to preoperative administration of Anthracycline-based regimen followed by Nab-paclitaxel and…
- Conditions
- Breast Cancer, HER-2 Positive Breast Cancer, Effects of Chemotherapy
- Trial name
- NCT01432223
- Testing
- Nab-paclitaxel
- Where
- Japan
- Volunteers
- 46 people
- Sponsor
- Osaka Medical College
Heart Failure
STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin.
- Trial name
- NCT02943590
- Testing
- Atorvastatin
- Where
- 4 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Magnetic Resonance Imaging (MRI) of Tumor Response and Cognitive Impairment in Breast Cancer Patients Undergoing Chemotherapy
We will use magnetic resonance imaging (MRI) to investigate tumor changes in women with breast cancer who are receiving anthracycline-based systemic chemotherapy.
- Trial name
- NCT01045044
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kettering Health Network
Breast Cancer, Heart Failure
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
- Trial name
- PROTECTAA (NCT06304857)
- Testing
- Dapagliflozin
- Where
- 3 sites in Poland
- Volunteers
- 188 people
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
Breast Cancer
Chemotherapy in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of annamycin liposomal in treating patients who have…
- Trial name
- NCT00012129
- Testing
- liposomal annamycin
- Where
- United States
- Sponsor
- NYU Langone Health
Cardiomyopathy Due to Anthracyclines
Stem Cell Injection in Cancer Survivors
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction…
- Trial name
- SENECA (NCT02509156)
- Testing
- Allo-MSCs
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- The University of Texas Health Science Center, Houston
Breast Cancer (Early Breast Cancer), Cardiotoxicity
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care.
- Conditions
- Breast Cancer (Early Breast Cancer), Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
- Trial name
- C-BREAST-01 (NCT07588425)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Fatih GURLER
Cardiomyopathy
Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
The primary objective of this study is to investigate whether giving prophylactic metoprolol prior to and during anthracycline or trastuzumab therapy will decrease the incidence of anthracycline-induced cardiomyopathy.
- Trial name
- NCT00806390
- Testing
- Metoprolol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer
Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients
The purpose of this study is to evaluate the overall response rate of Genexol-PM compared with paclitaxel (cremophor-based paclitaxel) as palliative chemotherapy in anthracycline-pretreated patients with metastatic breast cancer.
- Trial name
- NCT01169870
- Testing
- Genexol-PM, Paclitaxel
- Sponsor
- National Cancer Center, Korea
Metastatic Breast Cancer
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
- Trial name
- NCT01910870
- Testing
- Cisplatin, Metronomic Cyclophosphamide
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Jean Perrin
CINV
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
- Trial name
- NCT01857232
- Testing
- Ondansetron, Dexamethasone, Fosaprepitant
- Where
- Denmark
- Volunteers
- 342 people
- Sponsor
- Acacia Pharma Ltd
Chemotherapy Effect
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors
Early detection of cardiomyopathy in patients receiving Anthracycline chemotherapy and determine if speckle tracking echo and Troponin gene will add benefit for early detection of cardiomyopathy.
- Trial name
- NCT03381014
- Testing
- Chemotherapy, Cancer, Anthracyclines
- Volunteers
- 50 people
- Sponsor
- Assiut University
Anthracycline Related Cardiotoxicity in Breast Cancer
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function.
- Trial name
- NCT03934905
- Testing
- sulforaphane
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Texas Tech University Health Sciences Center
Metastatic Breast Cancer
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
This is a single-center, open, randomized, controlled phase 2 clinical trial designed to compare low-dose-bevacizumab and pemetrexed with TPC in metastatic HER2-negative breast cancer patients after failure of taxanes and…
- Trial name
- NCT02829008
- Testing
- low-dose-bevacizumab/pemetrexed, Treatment of physician's choice
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer, Doxorubicin Induced Cardiomyopathy
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing…
- Trial name
- NCT07370506
- Testing
- Telmisartan, Doxorubicin (DOX)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University